The potential benefits of precision medicine are immense. So are the challenges of delivering these benefits in a widespread, economically viable way. The rapid pace of discovery and change in cancer diagnosis and care has created a pervasive knowledge gap between what is possible and what is actually available for precision diagnosis and personalized treatment in the healthcare system. As an outgrowth of the Genomic Medicine Initiative at Harvard Medical School in 2009, we founded the Precision Medicine Network™ in 2011. Through Crosswalk Insight: Oncology we are enabling Fluency in the language of Precision Medicine™ and connecting providers, patients and payers into a network designed to accelerate the rational adoption of precision medicine everywhere.
Mark Boguski, M.D., Ph.D. is
Co-Founder and Chief Medical Officer of Precision Medicine Network™. He also serves on the faculty of Harvard Medical School and founded the Genomic Medicine Initiative at Beth Israel Deaconess Medical Center in Boston in 2009. Dr. Boguski is a pioneer in the fields of biomedical informatics and genomics and has previously held faculty positions at the Johns Hopkins University School of Medicine, the U.S. National Institutes of Health, the U.S. National Library of Medicine and as an executive in the biotechnology and pharmaceutical industries. He was the Founding Director of the Allen Institute for Brain Science and is a former Vice President of Novartis. Dr. Boguski is a Visionary and Influencer according to the Personalized Medicine Coalition and has been credited by Forbes as the originator of the term "precision medicine." Boguski is a member of the Institute of Medicine of the U.S. National Academies, the American College of Medical Informatics, the Society for Participatory Medicine and is also a Fellow of the College of American Pathologists. He is a graduate of the Medical Scientist Training Program at Washington University in St. Louis.
Our Crosswalk Insight Advisory Board members are pioneers in precision medicine. They include oncologists, pathologists and change agents with extensive experience in the science, technology and applications of precision diagnostics and targeted therapies. Our board is committed to advancing the practice of precision medicine everywhere through Crosswalk Insight™: Oncology.
Leonard Sender, M.D. is a world leader in translational research and the application of precision medicine science and technology for pediatric, adolescent and young adult cancer. He serves as Medical Director of the Hyundai Cancer Institute and Division Chief of Pediatric Oncology for Pediatric Subspecialty Faculty at Children's Hospital of Orange County, California. Dr. Sender is also Medical Director of Clinical Operations and Program Development and Director of the Young Adult Cancer Program at U.C. Irvine Medical Center's Chao Family Comprehensive Cancer Center. Dr. Sender serves as chairman of Stupid Cancer (stupidcancer.org) and is a founding member and chairman of SeventyK.org, an adolescent and young adult (AYA) cancer advocacy foundation. Dr. Sender's primary research interests lie in better understanding cancer and its impact on the AYA cancer patient. This interest is comprehensive and multidisciplinary, extending from epidemiological components and biological factors to the psychosocial impact of the disease. He also serves on the Board of Advisors for TEDMED, and is the Founder & Editor-in-Chief of the Journal of Adolescent and Young Adult Oncology (JAYAO) and founding President of the Society for Adolescent and Young Adult Oncology (SAYAO).
David G. Hicks, MD, is currently the Director of Surgical Pathology at the University of Rochester Medical Center.
Dr. Hicks is widely recognized as an expert in breast pathology. He is actively involved in improving the process and standards for how breast cancer is diagnosed and treated, serving as Co-Chairman of the ASCO/CAP Her-2 Testing in Breast Cancer Committee and on the ASCO/CAP ER/PR Full Panel Guideline Committee. Dr. Hicks is a passionate and effective educator, developing and teaching courses for breast cancer pathologists at CAP, and lecturing at various university and health care facilities around the country. He is a well published translational scientist, and an innovator in improving clinical efficiency and quality in surgical pathology for the precision diagnosis of cancer. His efforts to standardize the handling of tissue samples as they come from the operating room in order to minimize pre-analytic variables, and thus ensuring reliable results of diagnostic testing, is a critical component in the widespread adoption of precision medicine.
Dr. Hicks leads a subspecialty-based surgical pathology center of excellence, where he is intently focused on the molecular genetic profiling of clinical samples from patients with cancer. His research is directed at finding new molecular genetic markers to better understand the prognosis and guide therapeutic management of breast cancer.
Dr. Hicks earned his medical degree from the University of Rochester School of Medicine and Dentistry. His postgraduate training includes an internship in internal medicine and a residency in anatomic pathology at the Hospital of the University of Pennsylvania in Philadelphia.
Luis Diaz M.D. is a leading authority in oncology, having developed personalized diagnostic and therapeutic approaches for cancer. Dr. Diaz is a pioneer in circulating tumor DNA analyses in human cancer, having performed landmark studies in the field. He is Director of Translational Medicine at the Ludwig Center at Johns Hopkins and is board certified in Medical Oncology. He is also Founder and Chief Medical Officer of Personal Genome Diagnostics, a leading provider of proprietary, advanced cancer genome analysis services including CancerXome™, CancerSelect-R™, PlasmaSelect-R™ and METDetect-R™ to the healthcare marketplace including patients. These solutions help further the understanding of cancer and facilitate the development of new diagnostics and therapeutics to help researchers identify elusive cancer-related genetic changes. Dr. Diaz has undergraduate and medical degrees from the University of Michigan, and completed post-doctoral training at Johns Hopkins University.
Eric F. Glassy, M.D. is Board certified in Anatomic and Clinical Pathology with a specific interest in Hematopathology, Information Technology and Digital Pathology. He has served as Laboratory Director for several Southern California hospitals. Dr. Glassy is active in the College of American Pathologists where he has served or serves in leadership positions on the Hematology Resource Committee, Publications Committee, Council on Education, Council on Scientific Affairs, Committee on Member and Community Engagement, and the Council on Membership and Professional Development. He is a past board member of the CAP Foundation. He was honored by the CAP with the Pathologists’ Distinguished Service Award, the President's Honor Award and Excellence in Education Award. He is a well-known lecturer and has authored several publications in his fields of interest. He has also edited and illustrated the CAP Color Atlas of Hematology, Color Atlas of Body Fluids and the Color Atlas of Urinary Sediment. He is the developer of a variety of software programs for pathology. He holds a green belt in Six-Sigma. He is president elect of the Digital Pathology Association and chairs the CAP Digital Pathology Committee. Dr. Glassy received his medical degree from the University of California, San Francisco, California. He did his pathology residency and hematopathology fellowship at Harbor-UCLA Medical Center.
Samuel K. Caughron, M.D. is one of fewer than 200 physicians in the world with ABP board certification in Molecular Genetic Pathology and one of a very few who applies that training to clinical practice in a community setting. He is recognized nationally for his insight and expertise in translating advanced technologies into economically viable, real-world clinical solutions. Dr. Caughron has served as founding director of two molecular diagnostics laboratories, navigating the real-world challenges of bringing cutting edge molecular diagnostics to the care of community cancer patients. He has served on numerous national professional committees, boards and advisory panels, and currently serves as Vice-Chair of the College of American Pathologists (CAP) Personalized Healthcare Committee, as a member of the Association for Molecular Pathology (AMP) Economic Affairs Committee, and as a board member for the American Pathology Foundation (APF). Prior to entering medical practice, Dr. Caughron founded two information technology companies, and was a pioneer in the integration of medical information with mobile technology. He is a diplomate of the American Board of Pathology with certification in Anatomic and Clinical Pathology.
Gary M. Owens, M.D. is an expert in the evaluation and reimbursement of new drugs and devices, medical and health plan strategy, management and operations. In a career spanning 25 years in health care management, he has provided strategic and tactical guidance to employer benefit managers, pharmaceutical and device manufacturers and managed care plans. Dr. Owens also lectures widely on health care management topics and his articles and interviews have appeared in The American Journal of Managed Care, American Health and Drug Benefits, Specialty Pharmacy News, Oncology Times, Journal of Managed Care Medicine, Journal of Managed Care Pharmacy and Disease Management. From 2003-2006, Dr. Owens was Vice President for Medical Management and Policy at Independence Blue Cross (IBC) where he managed pharmacy operations for over 2.0 million members and was a leader in the evaluation and management of biotechnology drugs at the health plan. From 1996 to 2003, he was Vice President for Patient Care Management at IBC and was responsible for medical management services for 3.2 million members and nearly 7 billion dollars of annual medical spending activity. From 1986 to 1996 Dr. Owens was a Senior Medical Director at IBC and its affiliates, Keystone Health Plan East and Delaware Valley HMO.
We believe that knowledgeable and empowered patients who are proactively engaged with their care team help accelerate the transformation of health care. Our Empowered Patient Advisory Board provides the patient perspective on what it takes to effectively navigate the health system to access precision medicine. They inspire and inform our strategy as we build the Precision Medicine Network™.
St. Louis, Missouri
"It is my dream to see a world without cancer. From the day I was diagnosed, I began a mission to spread awareness and inspiration about colon cancer. My friends, family and others affected by this disease are what motivate me. I pray they will never have to endure what I had to. That’s what I wish to offer to you – a message of hope and power. Even in the most trying and difficult circumstances, whether they be physical, mental, or emotional, we can push through and overcome."
- Teri Griege
A native of St. Louis, MO, Teri Griege is a Mother, Wife and Survivor. She is an avid multi-sport athlete and began running marathons in her forties, including Chicago, Boston and New York. Her interest in endurance events led her to triathlons and she ultimately set her sights on the big prize: The Ironman World Championship in Kona, Hawaii.
When she completed Ironman Louisville in 2009, ten minutes slower than the prior year, she was certain something was wrong. Her suspicions were confirmed with a devastating diagnosis of Stage 4 colon cancer with metastases to her liver.
Teri did not give up and deepened her resolve to complete the Ironman World Championship. She trained for this grueling race while undergoing radiation treatments and chemotherapy, followed by colon and liver resections. Knowing she couldn’t do it alone, she assembled an army of supporters she called Teri’s Troops, including friends, family and doctors, who all helped her on her incredible journey.
On October 8, 2011, at age 50, Teri finished the Ironman World Championship achieving this amazing feat just two years after being diagnosed with Stage IV colon cancer and given a 6% chance of survival.
As a result of her diagnosis, each of her sisters had colonoscopies; one had precancerous polyps the other had stage 3 colon cancers. Two of their 4 daughters had precancerous polyps. Her sister will be the first to tell you—Teri saved her life. She would never have gone for screening had it not been for Teri.
Teri remains cancer free but continues to have monthly chemotherapy treatments and she also continues to participate in Ironman, Marathon and Cycling events including the 2013 London Marathon, running with her Husband David Griege. Teri travels the country to spread awareness and education about colon cancer. She has been featured on NBC’s Today Show and has received awards and recognition for her outstanding achievements.
Teri joined the Precision Medicine Network™ Empowered Patient Board as Co-Chairman in order to play an active role in helping others to learn from her story, and to be the difference in educating, and empowering others to fight their disease. She lives her life by these powerful words: Powered by Hope – Anything is Possible.
Sioux Falls, South Dakota
Matt Ellefson, a Christian, husband and father of five, was living an active and healthy lifestyle in 2009 when he awoke one morning and began to cough up blood. He was shocked when a biopsy revealed a diagnosis of advanced lung cancer. Without treatments, Matt was given eight months to live and with treatments, he was facing a five year survival rate of 5%.
With the help of his wife, Matt began searching for help. They were both disappointed in how difficult it was for them to navigate their way through the sea of information. It was at this time that Matt turned to God for help and the idea behind SURVIVEit was born. Upon completion of his first line of therapy, Matt quickly became an active cancer advocate and developed a passion for inspiring other cancer patients to become proactively engaged in their healing process. His cancer returned a second time in 2011 with metastasis to a node in his neck and a third time in 2012 with a metastasis to his brain.
Today, Matt continues treatment with Xalkori (crizotinib), a targeted ALK+ gene therapy, and lives an active life which includes running half marathons, cycling competitions, extreme sports, speaking engagements and exploring the world with his family. He serves as a spiritual mentor and national cancer advocate through his work with Celebrate Community Church, the American Cancer Society, American Lung Association, LUNGevity, Imerman Angels, and LIVESTRONG. He has been featured on SiriusXM Doctor’s Radio, the cover of BizNow Magazine and numerous print, radio and television broadcasts.
Matt has a dream of a world free from the fear of cancer and is committed to using what he’s learned from his cancer journey as well as his 28 year career in engineering, business development, and sales/marketing management to develop a series of tools to help anyone affected by cancer. In early 2013, Matt founded SURVIVEit, and is devoting his full time to the development of this web-based platform for anyone affected by cancer to research their disease, locate treatment options, rate cancer care, share experiences and support each other in their cancer journey.
Matt joined the Precision Medicine Network™ Empowered Patient Board as Co-Chairman in order to play an active role in helping others to learn from his story and to be the difference in educating, and empowering others to fight their disease.